Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhy combining these two medicines carries real clinical risk, and how to switch safely
The decision most people are actually facing: switch or stack?
A question our prescribers hear most weeks goes roughly like this: "I've been on Wegovy for a while and I've heard Mounjaro gets better results, can I take both while I transition?" The short answer is no, but the longer answer explains why the question makes sense and what the right path actually looks like.
Semaglutide (the medicine in Wegovy) is a GLP-1 receptor agonist. Tirzepatide (in Mounjaro) activates both the GLP-1 and GIP receptors. Because semaglutide already occupies the GLP-1 receptor, adding tirzepatide on top would hit that same pathway twice alongside the GIP pathway. There is no clinical trial evidence for this combination, and the cumulative effect on gastric motility, nausea, vomiting and heart rate could be severe. UK prescribers would not sanction it. The decision, then, is not whether to combine them, it's whether and when to switch from one to the other, and which suits your specific health picture. For a clear account of how these two medicines differ mechanically, that page covers the receptor science in detail.
If you are considering a switch, the standard clinical approach involves completing your current pen or pack, allowing a washout period that your prescriber determines based on both medicines' half-lives, and starting the new treatment at its lowest dose to let your body adjust. The precise timing is not something to judge alone.
What the evidence says about each medicine on its own
The clinical case for tirzepatide's weight-loss results is strong. In the SURMOUNT-1 trial, participants at the highest dose achieved an average body-weight reduction of around 20–21% over 72 weeks, as reported in the New England Journal of Medicine. The SURMOUNT-5 head-to-head trial (also published in the NEJM, 2025) compared tirzepatide directly against semaglutide 2.4mg in adults with obesity and found tirzepatide produced greater average weight loss over 72 weeks. NICE's appraisal of tirzepatide reflects this: see NICE technology appraisal TA1026 for the committee's full assessment.
Semaglutide's track record is well established too. The STEP 1 trial demonstrated an average reduction of roughly 15% over 68 weeks at the 2.4mg maintenance dose. The newer 7.2mg single-dose pen, approved by the MHRA in April 2026, has shown results approaching 20.7% in trials, narrowing the gap with tirzepatide considerably. Neither set of figures tells you what you personally will achieve. Biology, starting weight, adherence to lifestyle changes and how well you tolerate each medicine all shape the outcome. A side-by-side comparison of Wegovy and Mounjaro covers the results evidence in more depth.
| Factor | Semaglutide (Wegovy injection) | Tirzepatide (Mounjaro) |
|---|---|---|
| Receptor action | GLP-1 agonist | Dual GLP-1 and GIP agonist |
| UK weight-loss licence | Yes (BMI ≥30, or ≥27 with a weight-related condition) | Yes (BMI ≥30, or ≥27 with a weight-related condition) |
| Average trial weight loss (highest licensed dose) | ~15% at 2.4mg (STEP 1, 68 wks); ~20.7% at 7.2mg | ~20–21% at 15mg (SURMOUNT-1, 72 wks) |
| Head-to-head result | Comparator in SURMOUNT-5 | Greater average loss than semaglutide 2.4mg (SURMOUNT-5, NEJM 2025) |
| Can be combined with the other? | No (no clinical basis; overlapping pathways | No) same reason |
What about Ozempic, can that be combined with Mounjaro?
It comes up often, so it is worth being direct: Ozempic is semaglutide, licensed in the UK for type 2 diabetes, not for weight management. The NHS medicines page for semaglutide sets this out clearly. Using Ozempic for weight loss off-label and then asking whether it can overlap with tirzepatide compounds two problems: the off-label use itself, and the same combination risk described above. The answer is no on both counts. If you have seen this suggested online, the dedicated page on Ozempic and Mounjaro in the same week explains the full picture.
The same point applies to anyone wondering whether tirzepatide and semaglutide can be mixed in any form, different injections, different timing, different doses. The mechanism doesn't change with the schedule. These are not medicines that complement each other in combination; they compete for the same receptor sites and their effects are not additive in a controlled, predictable way.
How to make the right choice for you
The practical question (semaglutide or tirzepatide, and when to switch if you've tried one) is genuinely a clinical decision. Factors a prescriber weighs include your current dose and how well you are tolerating it, your weight-loss progress to date, any other medicines you take, and conditions in your health history that may favour one agent over the other. Cost is a consideration for many people too; an honest account of what Wegovy and Mounjaro each cost privately is worth reading before your consultation.
If you are already on one of these treatments and want to explore the other, bring that conversation to a prescriber. At nume, every repeat order and every switch request is reviewed by a GPhC-registered prescriber before anything is dispensed. There are no shortcuts here, and that is by design. You can read more about how we approach clinical oversight on our about us page, or explore what treatment options we offer on the weight-loss treatments overview. Which medicine suits you is a decision our prescribers make with you, based on your full picture, not a default.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.